Sign In
Buy VCYT
$56.97
-2.33 (-3.93%)
At Close: Jul 10, 2026
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
04:05pm, Thursday, 09'th Jul 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 af
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy
01:01pm, Wednesday, 08'th Jul 2026
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
09:05am, Saturday, 04'th Jul 2026
Chief Accounting Officer Jonathan Wygant sold 24,000 shares on May 22, 2026, generating a transaction value of ~$1.09 million at an average price around $45.40 per share. This transaction reduced dire
Veracyte Stock Surges 117% in a Year: What's Driving the Rally?
03:16pm, Thursday, 02'nd Jul 2026
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
12:49pm, Saturday, 27'th Jun 2026
A director of Veracyte reported selling 3,729 shares for a transaction value of approximately $197K on June 18, 2026. This disposition represented roughly 20% of Karin Eastham's direct common stock ho
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
10:52am, Thursday, 11'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
10:46am, Tuesday, 09'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
01:13pm, Thursday, 04'th Jun 2026
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
12:35pm, Thursday, 04'th Jun 2026
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
05:14pm, Monday, 01'st Jun 2026
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
08:00am, Monday, 01'st Jun 2026
On the heels of the landmark [url="]OPTIMA trial[/url] readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostic
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
07:30am, Monday, 01'st Jun 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
[url="]Veracyte, Inc.[/url] (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the [url="]ENZAMET trial[/url] presented at the
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoi
